{"id":"safinamide-as-add-on-therapy","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dizziness"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Insomnia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting MAO-B, Safinamide increases the levels of dopamine in the brain, which can help alleviate symptoms of Parkinson's disease. Additionally, its weak inhibitory effect on MAO-A may contribute to its therapeutic effects.","oneSentence":"Safinamide is a monoamine oxidase B (MAO-B) inhibitor that also has a weak inhibitory effect on monoamine oxidase A (MAO-A).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:08.398Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"},{"name":"Major depressive disorder"}]},"trialDetails":[{"nctId":"NCT05312632","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South Korea","status":"COMPLETED","sponsor":"Eisai Korea Inc.","startDate":"2022-04-05","conditions":"Parkinson Disease","enrollment":201},{"nctId":"NCT03994328","phase":"","title":"An Observational Study on Safinamide, Rasagiline and Other Standard of Care in PD","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-12-03","conditions":"Parkinson's Disease","enrollment":1235},{"nctId":"NCT03881371","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-08-01","conditions":"Parkinson Disease","enrollment":307},{"nctId":"NCT03841604","phase":"PHASE4","title":"Effect of Safinamide on Parkinson's Disease Related Chronic Pain","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-04-09","conditions":"Idiopathic Parkinson Disease","enrollment":94},{"nctId":"NCT03753763","phase":"PHASE2","title":"Safinamide for Multiple System Atrophy (MSA)","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-10-29","conditions":"Multiple System Atrophy","enrollment":49},{"nctId":"NCT00605683","phase":"PHASE3","title":"MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist","status":"COMPLETED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2007-11","conditions":"Idiopathic Parkinson's Disease","enrollment":679},{"nctId":"NCT01028586","phase":"PHASE3","title":"MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)","status":"TERMINATED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2009-10","conditions":"Idiopathic Parkinson's Disease","enrollment":507},{"nctId":"NCT00627640","phase":"PHASE3","title":"Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa","status":"COMPLETED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2009-02","conditions":"Idiopathic Parkinson's Disease","enrollment":549},{"nctId":"NCT01286935","phase":"PHASE3","title":"18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD","status":"COMPLETED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2007-08","conditions":"Parkinson's Disease","enrollment":544},{"nctId":"NCT01187966","phase":"PHASE3","title":"Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease","status":"COMPLETED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2007-01","conditions":"Parkinson's Disease","enrollment":669},{"nctId":"NCT00643045","phase":"PHASE3","title":"Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist","status":"COMPLETED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2004-12","conditions":"Idiopathic Parkinson's Disease","enrollment":269},{"nctId":"NCT00642889","phase":"PHASE3","title":"Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)","status":"COMPLETED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2005-06","conditions":"Parkinson's Disease","enrollment":227}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Apokyn","Parlodel","Mirapex","Requip","Cabergoline (not approved in US)"],"phase":"phase_3","status":"active","brandName":"Safinamide (as add-on therapy)","genericName":"Safinamide (as add-on therapy)","companyName":"Newron Pharmaceuticals SPA","companyId":"newron-pharmaceuticals-spa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Safinamide is a monoamine oxidase B (MAO-B) inhibitor that also has a weak inhibitory effect on monoamine oxidase A (MAO-A). Used for Parkinson's disease, Major depressive disorder.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}